Loading organizations...
§ Private Profile · Seoul, Seoul-t'ukpyolsi, South Korea
Biotechnology company developing small molecule anticancer drugs for oncology, focused on synthetic lethality and DNA damage response.
Avelos Therapeutics is a Seoul, South Korea-based precision medicine company that discovers and develops small molecule anticancer drugs targeting synthetic lethality, cell cycle regulation, and DNA damage response pathways. The early clinical-stage enterprise focuses on biomarker-driven oncology therapeutics to address historically undruggable cancer targets and currently maintains four proprietary drug pipelines, including its lead oral medication candidate AD1208 and preclinical asset AVS1001. Operating with an out-licensing and commercialization business model, the organization has raised approximately $21.7 million in total funding to date, which includes a $12.3 million Series B financing round completed in April 2024. This venture capital-backed business has secured financial backing from notable institutional investors such as Statts Investment, SV Investment, Mirae Asset Venture Investment, and LSK Investment. Avelos Therapeutics was founded in 2021 by Young-Whan Park, Soongyu Choi, and Kangsik Yun.
Avelos Therapeutics has raised $20.5M across 2 funding rounds.
Avelos Therapeutics has raised $20.5M in total across 2 funding rounds.
Avelos Therapeutics has raised $20.5M across 2 funding rounds. Most recently, it raised $12.5M Series B in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 9, 2024 | $12.5M Series B | — | — | Announced |
| Aug 22, 2022 | $8M Series A | Mirae Asset Capital, Mirae Asset Venture Investment, Quad Investment Management, SV Investment, Timefolio Asset Management, UTC Investment | — | Announced |
Avelos Therapeutics has raised $20.5M in total across 2 funding rounds.
Avelos Therapeutics's investors include Mirae Asset Capital, Mirae Asset Venture Investment, QUAD Investment Management, SV Investment, Timefolio Asset Management, UTC Investment.